RenovoRx

Dr. Jonathan Kessler, Chief of Interventional Radiology at City of Hope, recently joined the Living Hope Podcast to discuss his work with a multidisciplinary oncology team treating and the need for new treatment options. He highlighted the potential of RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) therapy platform to enhance local drug-delivery in difficult-to-treat tumors while potentially reducing the toxicities associated with systemic chemotherapy.

Listen to the episode here: https://bit.ly/4veDHJy

RenovoCath is cleared by FDA for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial study conducted under an IND.

Ramtin Agah, MD, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder comments on the recently published peer-reviewed case study from researchers at Moffitt Cancer Center supporting the procedural flexibility and targeted delivery capabilities of our TAMP platform enabled by RenovoCath. Read more: https://bit.ly/4owgpft

Leesa Gentry, Chief Clinical Officer of RenovoRx, comments on the Company’s recently granted FDA Orphan Drug Designation to oxaliplatin for the treatment of pancreatic cancer. This designation further supports the versatility of RenovoRx's novel approach to delivering multiple therapeutic agents directly near the tumor site. https://bit.ly/3RBqdsf